Need-driven Treatment of the Patients With Type 1 Diabetes

Launched by TAMPERE UNIVERSITY HOSPITAL · Aug 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether people with type 1 diabetes who have good blood sugar control can safely have their regular in-person diabetes check-ups less often—every two years instead of every year—while still being monitored remotely. The goal is to see if this approach helps keep blood sugar levels stable over a two-year period. Participants will visit the clinic twice: once at the start and once after 24 months, where doctors will do thorough health checks and review blood sugar data. There will also be a remote check-in at 12 months to renew prescriptions and look at glucose readings. Throughout the study, participants can reach out to their healthcare team whenever they need.

To take part, individuals must be adults with type 1 diabetes for at least one year, using insulin either by multiple daily injections or a pump, and have good recent blood sugar control, which is measured by specific targets using a continuous glucose monitor (a device that tracks blood sugar throughout the day). Participants also need to be under specialist diabetes care in a specific region in Finland and willing to share their glucose data remotely with their care team. This study aims to find out if less frequent in-person visits combined with remote monitoring can be a safe, convenient way to manage diabetes for those who are stable and well-controlled.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Diagnosis of type 1 diabetes
• • Treatment with multiple daily injections or insulin pump therapy
• • Duration of diabetes ≥ 1 year
• * Good glycemic control over the previous two weeks, defined as:
• • HbA1c \< 53 mmol/mol
• • Time in Range (TIR) \> 70%
• • Time Below Range (TBR) \< 4%
• • Time Above Range (TAR) \< 25%
• • Use of a continuous glucose monitoring system connected via a smartphone application
• • Under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)
• • Willing to accept remote diabetes care by granting the diabetes team at Tampere University Hospital access to glucose data
• • No need for regular specialist care due to other medical conditions
• • Provides informed consent to participate in the study
• Exclusion Criteria:
• • Age \< 18 years
• • Duration of diabetes \< 1 year
• • Pregnancy
• • Not using multiple daily injections or insulin pump therapy
• • Not using a continuous glucose monitoring system
• • Does not accept remote care
• • History of diabetic ketoacidosis or severe hypoglycemia within the past 12 months
• • Presence of retinopathy
• • No retinal imaging performed within the past 12 months
• • Urine albumin-creatinine ratio (uACR) \> 3 mg/mmol or estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73 m² on two occasions over a period of more than 3 months
• • Undergoing dialysis or post-kidney transplantation
• • Cardiovascular disease (excluding hypertension)
• • Neuropathy, foot ulcer, or amputation (foot risk category 1-3)
• • Scheduled hospital outpatient visits for other specialties within the next 12 months
• • Not under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)